Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved an update to the U.S. prescribing information for WINREVAIR™ (sotatercept-csrk).
Summit Therapeutics (NASDAQ:SMMT) announced that data from the Phase III HARMONi-GI1 trial evaluating ivonescimab, a potential first-in-class investigational bispecific antibody, will be presented at the Presidential Symposium II during the European Society for Medical Oncology (ESMO) 2026 Congress.
Pharming Group (NASDAQ:PHAR) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation caused by PI3Kδ signaling abnormalities.
AbbVie (NYSE:ABBV) announced that the European Commission has approved RINVOQ® (upadacitinib) 15 mg tablets and 1 mg/mL oral solution for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA).
ADARx Pharmaceuticals announced plans to pursue a U.S. initial public offering that could value the rare disease-focused biotechnology company at up to approximately $1.74 billion.
Tiziana Life Sciences (NASDAQ:TLSA) announced that the final patient has completed the final visit in its Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
NewAmsterdam Pharma (NASDAQ:NAMS) and partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo® (10 mg obicetrapib monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe).
Anixa Biosciences (NASDAQ:ANIX) announced that it received its first Australian composition-of-matter patent for its breast cancer vaccine technology.
Johnson & Johnson (NYSE:JNJ) announced positive topline results from a pivotal Phase 3 trial evaluating CAPLYTA® (lumateperone) 42 mg once daily for the treatment of acute manic episodes in adults with bipolar I disorder.
AbbVie (NYSE:ABBV) announced a multi-year collaboration with Iambic Therapeutics to apply artificial intelligence technologies to discover and develop small molecule therapies.
Helus Pharma (NASDAQ:HELP) presented four posters on its investigational oral deuterated psilocin analog HLP003 for major depressive disorder (MDD) at Psych Congress 2026 in New Orleans.
Alkermes (NASDAQ:ALKS) reported positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, an investigational orexin 2 receptor agonist being developed for attention-deficit hyperactivity disorder (ADHD).
